Quarterly Activities Report & Appendix 4C, 30 September 2016
Filed with ASX · · 9 pages · English
• Achieved 23% quarter on quarter sales growth • Achieved 11% higher average revenue per test receipt than that achieved over FY16 • Activated promotional campaign around the Susan G. Komen ® Dallas Race for the Cure ® • Strong cash position, with $8.9m in cash Melbourne, Australia, 27 October 2016: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), a molecular diagnostics company s
Genetic Technologies Limited on 6ix
Story so far
Earlier from Genetic Technologies
- Appendix 4E & Financial Report 2016
- Quarterly Activities Report & Appendix 4C - 30 June 2016
- New Generation Test - BREVAGenplus Launch
- Appendix 4D and 31 December 2015 Half Year Financial Report
- Partnership to promote BREVAGenplus
Later from Genetic Technologies
- License Agreement to Develop Colorectal Cancer Risk Test
- AUD 8.1 Million Capital Raising
- Quarterly Activities Report & Appendix 4C - 31 December 2016
- Appendix 4D and 31 December 2016 Half Year Financial Report
- Partnership to Promote BREVAGenplus, Second Year
Follow Genetic Technologies into a list and get an email when it puts out news.
Follow Genetic Technologies